Date: 2014-12-09
Type of information: Nomination
Compound: member of the board of directors
Company: Pharnext (France)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On December 9, 2014, Pharnext announced the nomination of Michel de Rosen to its board of directors. The wealth of expertise Michel de Rosen has cultivated during his time as an executive in the pharmaceutical and biotechnology industries will be an asset to Pharnext moving forward. For nearly 25 years, Michel de Rosen held various executive positions at Rhone-Poulenc, in particular in its pharmaceutical subsidiary Rhone-Poulenc Rorer, now known as Sanofi, and then at ViroPharma. While at Rhone-Poulenc, from 1983 to 1999, Michel de Rosen successively served as president and chief executive officer of Pharmuka, Rhone-Poulenc Fibers and Polymers, and then Rhone-Poulenc Rorer in the United States. From 2000 to 2008, as chief executive officer of ViroPharma, he successfully transformed the company, recently purchased by Shire. After 15 years in the United States, Michel de Rosen returned to France.
Financial terms:
Latest news:
Is general: Yes
